<bill session="117" type="s" number="1898" updated="2023-01-11T13:49:59Z">
  <state datetime="2021-05-27">REFERRED</state>
  <status>
    <introduced datetime="2021-05-27"/>
  </status>
  <introduced datetime="2021-05-27"/>
  <titles>
    <title type="display">Affordable Medications Act</title>
    <title type="official" as="introduced">A bill to ensure medications are affordable.</title>
    <title type="short" as="introduced">Affordable Medications Act</title>
  </titles>
  <sponsor bioguide_id="S001203"/>
  <cosponsors>
    <cosponsor bioguide_id="B001230" joined="2021-05-27"/>
    <cosponsor bioguide_id="B001277" joined="2021-05-27"/>
    <cosponsor bioguide_id="B001288" joined="2021-05-27"/>
    <cosponsor bioguide_id="B000944" joined="2021-05-27"/>
    <cosponsor bioguide_id="D000563" joined="2021-05-27"/>
    <cosponsor bioguide_id="G000555" joined="2021-05-27"/>
    <cosponsor bioguide_id="H001076" joined="2021-05-27"/>
    <cosponsor bioguide_id="K000367" joined="2021-05-27"/>
    <cosponsor bioguide_id="M001176" joined="2021-05-27"/>
    <cosponsor bioguide_id="R000122" joined="2021-05-27"/>
    <cosponsor bioguide_id="S000033" joined="2021-05-27"/>
    <cosponsor bioguide_id="W000817" joined="2021-05-27"/>
    <cosponsor bioguide_id="W000802" joined="2021-05-27"/>
  </cosponsors>
  <actions>
    <action datetime="2021-05-27">
      <text>Introduced in Senate</text>
    </action>
    <action datetime="2021-05-27" state="REFERRED">
      <text>Read twice and referred to the Committee on Finance.</text>
    </action>
  </actions>
  <committees>
    <committee code="SSFI" name="Senate Finance" subcommittee="" activity="Referral"/>
  </committees>
  <relatedbills>
    <bill session="117" type="h" number="2181" relation="unknown"/>
    <bill session="117" type="s" number="141" relation="unknown"/>
    <bill session="117" type="s" number="920" relation="unknown"/>
    <bill session="117" type="s" number="3339" relation="unknown"/>
    <bill session="117" type="h" number="6392" relation="unknown"/>
    <bill session="117" type="h" number="7828" relation="unknown"/>
  </relatedbills>
  <subjects>
    <term name="Health"/>
    <term name="Administrative law and regulatory procedures"/>
    <term name="Canada"/>
    <term name="Civil actions and liability"/>
    <term name="Congressional oversight"/>
    <term name="Department of Health and Human Services"/>
    <term name="Digestive and metabolic diseases"/>
    <term name="Drug safety, medical device, and laboratory regulation"/>
    <term name="Executive agency funding and structure"/>
    <term name="Government information and archives"/>
    <term name="Government studies and investigations"/>
    <term name="Health care costs and insurance"/>
    <term name="Infectious and parasitic diseases"/>
    <term name="Inflation and prices"/>
    <term name="Intellectual property"/>
    <term name="Marketing and advertising"/>
    <term name="Medicaid"/>
    <term name="Medical research"/>
    <term name="Medicare"/>
    <term name="National Institutes of Health (NIH)"/>
    <term name="Prescription drugs"/>
    <term name="Public contracts and procurement"/>
    <term name="Retail and wholesale trades"/>
    <term name="Sales and excise taxes"/>
    <term name="Trade restrictions"/>
    <term name="User charges and fees"/>
  </subjects>
  <amendments/>
  <summary date="2021-08-05T21:58:09Z" status="Introduced in Senate">Affordable Medications Act

This bill revises and expands various requirements relating to prescription drug pricing and affordability.&#160;

Specifically, the bill expands financial reporting requirements for drug manufacturers&#160;and establishes corresponding civil penalties for noncompliance; it also adds reporting requirements for certain nonprofit patient-assistance programs.

Further, the bill requires the Centers for Medicare &amp; Medicaid Services (CMS) to negotiate prices for certain prescription drugs under Medicare and requires the Centers for Medicare and Medicaid Innovation within the CMS to test specified models for negotiating drug prices. It also establishes reporting requirements, and corresponding civil penalties for noncompliance,&#160;for pharmaceutical companies with respect to spikes in prescription drug prices.

The bill establishes an excise tax on prescription drugs subject to price spikes, lessens prescription drug cost-sharing requirements under qualified health plans and group health plans, and modifies requirements for the importation of prescription drugs.

It also requires drug manufacturers to provide rebates for drugs dispensed to certain low-income individuals under the Medicare program and limits the time frame that trade agreements are required to provide market exclusivity for biological products.

Additionally, the bill (1) requires the Food and Drug Administration to establish a database of generic drugs; (2) modifies other provisions related to generic drugs, prescription drug advertising, disclosure of wholesale acquisition prices, and patent-infringement proceedings; and (3) revises certain time frames and conditions related to drug exclusivity.

Finally, it establishes an innovation incentive fund for new or more effective treatments of bacterial infections and establishes the Center for Clinical Research within the National Institutes of Health.</summary>
</bill>
